The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it.

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Novo Nordisk A/S growth is driven by global obesity drug demand, robust pipeline development and manufacturing scale. Read ...

Is Trump's icy silence revealing a family feud? Critics are abuzz after a strange pause and topic shift in response to a ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

Eli Lilly and Novo Nordisk have agreed to sell their weight loss drugs, Wegovy and Zepbound, through the new TrumpRx ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies ...

Pfizer enters the lucrative weight-loss drug market with a massive $10 billion Metsera acquisition, targeting a $150-200 ...

WeightWatchers intends to offer Novo Nordisk’s pill version of Wegovy if it makes its US debut next year following potential ...

Weight-loss drug developer Zealand Pharma said it halted work on an early-stage obesity treatment candidate to focus on more promising programs, including one for which it teamed up with Swiss giant ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity ...